Biochemical modulation as an approach to reversal of antimetabolite resistance.
O'Dwyer
P J
PJ
Department of Medicine, Fox Chase Cancer Center, Philadelphia, PA 19111.
D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology*; D001224:Aspartic Acid / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D015195:Drug Design; D018432:Drug Resistance, Multiple; D005472:Fluorouracil / Q000494:pharmacology; D006801:Humans; D007372:Interferons / Q000494:pharmacology; D008778:Methylthioinosine / Q000494:pharmacology; D015337:Multicenter Studies as Topic; D010746:Phosphonoacetic Acid / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D011687:Purines / Q000378:metabolism; D011743:Pyrimidines / Q000378:metabolism; D013940:Thymidylate Synthase / Q000037:antagonists & inhibitors; D014407:Tumor Cells, Cultured / Q000187:drug effects
D000964:Antimetabolites, Antineoplastic; D011687:Purines; D011743:Pyrimidines; D001224:Aspartic Acid; D008778:Methylthioinosine; C013195:sparfosic acid; D007372:Interferons; D013940:Thymidylate Synthase; D010746:Phosphonoacetic Acid; D005472:Fluorouracil